Howie and Harlan are joined by Hil Moss, a graduate of Yale SOM and the Yale School of Public Health, to discuss her experience being diagnosed with breast cancer while a Yale student, the challenges facing cancer survivors after treatment, and the virtual clinic that she founded to help fill the void. Harlan reports on highly effective new obesity treatments on the horizon; Howie discusses the far-reaching effects of the Dobbs ruling, one year later.

Links:

“Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA”

American Diabetes Association: “American Diabetes Association Highlights Novel Agent Retatrutide which Results in Substantial Weight Reduction in People with Obesity or Type 2 Diabetes During Late Breaking Symposium”

“Experimental Lilly pill, Mounjaro both lead to 15% weight loss in clinical trials”

Hil Moss: About

VivorCare: The First Virtual Cancer Survivorship Clinic

Hil Moss: “Enough pink: We’re doing Breast Cancer Awareness Month all wrong”

“Dobbs v. Jackson Women’s Health Organization (2022)”

“A National Survey of OBGYNs’ Experiences After Dobbs”

“Indiana board reprimands Dr. Caitlin Bernard over 10-year-old's abortion case”

Learn more about the MBA for Executives program at Yale SOM.

Email Howie and Harlan comments or questions.

Mark Wolynn: It Didn’t Start With You